Moreover, the depletion of CD4+ CD25+ FoxP3 Tregs improves the efficacy cancer immunotherapies, such as checkpoint inhibitors, enhances the immune response and prolongs the survival of tumor patients [24]. This evidence concerns the gene CD4 and neoplasm.